Year: 2025
Type: article
Abstract: Description CCR7+dendritic cells (DC) are associated with favorable responses to immune checkpoint blockade. They have been found in intratumoral niches in proximity of CD4+ and CD8+ T cells. How CCR7+DC control intratumoral T cell infiltration, restrain intratumoral responses, and influence cancer outcomes is not fully understood. Here we show that, by limiting the expression of activation marker CD83 on CCR7+DC, we could increase the intratumoral amount of CD8 T cells and control cancer in mice. Reduction of membrane-bound CD83 determines a pro-inflammatory CCR7+DC state that correlates with the expansion of intermediate effector-like CD8 and tumor control. Additionally, CD83 levels on CCR7+DC negatively correlate with intratumoral CD8 T cell infiltration in distinct human cancers. These observations reveal that CD83 on CCR7+DC is a cellular and molecular tumor checkpoint that limits CD8 T cell immune-responses and has the potential to be exploited in cancer treatment. Funding Sources Cancer Prevention and Research Institute of Texas (CPRIT; RR210017) Robert J. Kleberg, Jr. and Helen C. Foundation Melanoma SPORE Developmental Research Program (DRP; P50CA221703) American Association of Immunologists (AAI) Intersect Fellowship (AWD00007355) Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Source: The Journal of Immunology
Authors: Mauro Di Pilato, Ruparoshni Jayabalan, Ricardo Gonzalez-Delgado, Luis Castillo Montanez, Jing Pan, Ruoxing Li, Andreas B Wild, Alexander Steinkasserer, Ziyi Li
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4416447434
FWCI:
Cites:
Cited by:
Related to:
